Makena Active Ingredient Compounding Ban Gets US FDA Panel Nod

 
• By Sue Sutter

The Pharmacy Compounding Advisory Committee unanimously voted to add hydroxyprogesterone caproate products for reducing the risk of recurrent singleton spontaneous preterm birth to the Withdrawn or Removed List under sections 503A and 503B of the Food, Drug and Cosmetic Act.

Sunset
The sun is quickly setting on compounding of HPC for preterm birth prevention. (Shutterstock)

More from US Advisory Committees

More from Pathways & Standards